Follow-on RifAximin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): a randomised placebo controlled trial

BACKGROUND: Clostridium difficile infection (CDI) recurs after initial treatment in approximately one in four patients. A single-centre pilot study suggested that this could be reduced using ‘follow-on’ rifaximin treatment. We aimed to assess the efficacy of rifaximin treatment in preventing recurre...

Descripción completa

Detalles Bibliográficos
Autores principales: Major, Giles, Bradshaw, Lucy, Boota, Nafisa, Sprange, Kirsty, Diggle, Mathew, Montgomery, Alan, Jawhari, Aida, Spiller, Robin C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Colon
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582824/
https://www.ncbi.nlm.nih.gov/pubmed/30254135
http://dx.doi.org/10.1136/gutjnl-2018-316794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582824/
https://www.ncbi.nlm.nih.gov/pubmed/30254135
http://dx.doi.org/10.1136/gutjnl-2018-316794

Ejemplares similares